Evidence map›Paper›PMID 35807161›Full record

ArticleJournal of clinical medicine2022

Galectin 3 (

Zoran Kovacevic, Tatjana Lazarevic, Nela Maksimovic, Milka Grk, Vladislav Volarevic, Marina Gazdic Jankovic, Svetlana Djukic, Katarina Janicijevic, Marina Miletic Kovacevic, Biljana Ljujic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zoran KovacevicClinic of Nephrology, University Clinical Center, 34000 Kragujevac, Serbia.
Tatjana LazarevicClinic of Nephrology, University Clinical Center, 34000 Kragujevac, Serbia.
Nela MaksimovicFaculty of Medicine, Institute of Human Genetics, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-5815-573X
Milka GrkFaculty of Medicine, Institute of Human Genetics, University of Belgrade, 11000 Belgrade, Serbia.
Vladislav VolarevicFaculty of Medical Sciences, Department of Microbiology and Immunology, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0001-5948-9902
Marina Gazdic JankovicFaculty of Medical Sciences, Department of Genetics, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0001-8151-9004
Svetlana DjukicFaculty of Medical Sciences, Department of Internal Medicine, University of Kragujevac, 34000 Kragujevac, Serbia.
Katarina JanicijevicFaculty of Medical Sciences, Department of Social Medicine, University of Kragujevac, 34000 Kragujevac, Serbia.
Marina Miletic KovacevicFaculty of Medical Sciences, Department of Histology and Embryology, University of Kragujevac, 34000 Kragujevac, Serbia.
Biljana LjujicFaculty of Medical Sciences, Department of Genetics, University of Kragujevac, 34000 Kragujevac, Serbia.
University of Kragujevac · RSUniversity of Belgrade · RSClinical Centre of Kragujevac · RS

Funding

Faculty of Medical Sciences, University of Kragujevac, Serbia JP 25/19; JP 06/20 and JP 24/20Ministry of Education, Science and Technological Development of the Republic of Serbia 175103
6 · The paper itself

Abstract

Galectin 3 plays a significant role in the development of chronic renal failure, particularly end-stage renal disease (ESRD). The aim of our study was to investigate the association between Gal-3 and biochemical parameters and primary disease in ESRD patients, by exploring the polymorphisms

Indexed as

arterial hypertensiondiabetes mellitusend-stage renal diseasegalectin 3polymorphisms

Identifiers

PMID35807161
PMCPMC9267120
OpenAlexW4283795735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.